- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05097053
A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19
A Parallel Group, Prospective, Randomized, Two-arm, Open-label Study to Evaluate the Immunogenicity, Safety, and Tolerability of Heterologous 3rd Boost of MVC-COV1901 in Adults With 2 Doses of ChAdOx1-nCov-19 in 3 Months and 6 Months
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This a parallel group, prospective, randomized, two-arm, open-label, single-center study to be conducted in approximately 200 healthy participants aged 20 to 64 years who have had their two doses of ChAdOx1-nCov-19 (Astra Zeneca). Preparation and administration of study intervention will be performed by authorized unblinded site personnel. Eligible participants will receive MVC-COV1901 vaccine after a 3-month (Group A: < 16 weeks and ≥ 12 weeks) or 6-month (Group B: < 28 weeks and ≥ 24 weeks) interval apart from their second dose of ChAdOx1-nCov-19.
The study consists of 6 on-site visits:
- Day -28 to Day 1, Visit 1 (Screening)
- Day 1, Visit 2 (study intervention) : randomization Group A and B
Group A:
- Day 1, Visit 2: treatment
- Day 29 ± 3 days, Visit 3
- Day 85 ± 3 days, Visit 4
- Day 169 ± 3 days, Visit 5
Group B:
- Day 1, Visit 2
- Day 85 ± 3 days, Visit 3: treatment
- Day 113 ± 3 days, Visit 4
- Day 169 ± 3 days, Visit 5
Studietype
Inschrijving (Verwacht)
Fase
- Fase 4
Contacten en locaties
Studiecontact
- Naam: Chieh-Yu Cheng, MD.PhD.
- Telefoonnummer: 8311 +886-3-3699721
- E-mail: s841060@gm.ym.edu.tw
Studie Contact Back-up
- Naam: Shu-Hsing Cheng, MD.PhD.
- Telefoonnummer: 8311 +886-3-3699721
- E-mail: shcheng@mail.tygh.gov.tw
Studie Locaties
-
-
-
Taoyuan, Taiwan
- Werving
- Taoyuan General Hospital
-
Contact:
- Chieh-Yu Cheng, M.D., Ph.D.
- Telefoonnummer: 8311 +886-3-3699721
- E-mail: s841060@gm.ym.edu.tw
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Male or female participant aged 20 to 64 years at randomization.
- Has received two doses of the ChAdOx1-nCov-19 (Astra-Zeneca) 12 to 16 weeks before randomization.
Female participant must:
- Be either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal;
- Or, if of childbearing potential, be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following the last administration of study intervention. Acceptable forms include:
i.Implanted hormonal methods of contraception or placement of an intrauterine device or intrauterine system ii.Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository c.Have a negative pregnancy test
- Participant is willing and able to comply with all required study visits and follow-up required by this protocol.
- Participant or the participant's legal representative must understand the procedures of the study and provide written informed consent.
Exclusion Criteria:
- Pregnant or breast feeding or have plan to become pregnant within 30 days after the last administration of study intervention.
- Currently receiving or received any investigational intervention within 30 days prior to the first dose of study intervention.
- Administered any licensed live-attenuated vaccines within 28 days or other licensed non-live-attenuated vaccines within 7 days prior to the first dose of study intervention.
- Administered any blood product or intravenous immunoglobulin administration within 12 weeks prior to the first dose of study intervention.
- Currently receiving or anticipate to receive concomitant immunosuppressive or immune-modifying therapy (excluding inhaled, topical skin and/or eye drop-containing corticosteroids, low-dose methotrexate, or < 2 weeks of daily receipt of prednisone less than 20 mg or equivalent) within 12 weeks prior to the first dose of study intervention.
- Currently receiving or anticipate to receive treatment with tumor necrosis factor (TNF)-α inhibitors, e.g. infliximab, adalimumab, etanercept within 12 weeks prior to the first dose of study intervention.
- Major surgery or any radiation therapy within 12 weeks prior to the first dose of study intervention.
- Has received any other investigational or licensed COVID-19 vaccine.
- Immunosuppressive illness or immunodeficient state, including hematologic malignancy, history of solid organ, bone marrow transplantation, or asplenia.
- A history of malignancy with potential risk for recurrence after curative treatment, or current diagnosis of or treatment for cancer (exceptions are squamous and basal cell carcinomas of the skin and treated uterine cervical carcinoma in situ, at the discretion of the investigator).
- Bleeding disorder considered a contraindication to IM injection or phlebotomy.
- Known SARS-CoV-2 infection in the recent 3 months prior to the first dose of study intervention.
- A history of cerebral venous sinus thrombosis, heparin-induced thrombocytopenia or antiphospholipid syndrome.
- Participant who, in the investigator's judgement, is not in a stable condition and by participating in the study could adversely affect the safety of the participant, interfere with adherence to study requirements or evaluation of any study endpoint. This may include a participant with ongoing acute diseases, severe infections, autoimmune disease, laboratory abnormality or serious medical conditions in the following systems: cardiovascular, pulmonary, hepatic, neurologic, metabolic, renal, or psychiatric.
- A history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901.
- Body (oral, rectal, or ear) temperature ≥ 38.0°C or acute illness (not including minor illnesses such as diarrhea or mild upper respiratory tract infection at the discretion of the investigator) within 2 days before the first dose of study intervention.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: MVC-COV1901 vaccine (3-month Interval)
There will be approximately 100 participants (Group A) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 1
|
MVC-COV1901 vaccine after a 3-month Interval
|
Experimenteel: MVC-COV1901 vaccine (6-month Interval)
There will be approximately 100 participants (Group B) who had received 2 doses of ChAdOx1-nCov-19 and will be vaccinated with MVC-COV1901 at Day 85.
|
MVC-COV1901 vaccine after a 6-month Interval
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Primary Immunogenicity
Tijdsspanne: Day1 to 28 days after vaccination
|
To evaluate the immunogenicity of heterologous third-boost (MVC-COV1901) in 3 months, compared to 6 months, in terms of neutralizing antibody Geometric Mean Titers (GMT) |
Day1 to 28 days after vaccination
|
Primary Safety
Tijdsspanne: Day1 to 28 days after vaccination
|
To evaluate the safety and tolerability of heterologous third-boost (MVC-COV1901) from Day 1 to 28 days after the study intervention The number and percentage of participants with the occurrence of:
|
Day1 to 28 days after vaccination
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Secondary Immunogenicity
Tijdsspanne: Day 1 and Day 169
|
To evaluate the immunogenicity of heterologous third-boost (MVC-COV1901) in terms of antigen-specific immunoglobulin titers GMT |
Day 1 and Day 169
|
Secondary Safety
Tijdsspanne: Day 1 to Day169
|
To evaluate the safety of heterologous third-boost (MVC-COV1901), over the study period The number and percentage of participants with the occurrence of:
|
Day 1 to Day169
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Exploratory Efficacy
Tijdsspanne: Day 1 to Day 169
|
To estimate the efficacy of heterologous third-boost (MVC COV1901), in the prevention of COVID-19
|
Day 1 to Day 169
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Chieh-Yu Cheng, MD.PhD., Taoyuan General Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Verwacht)
Studie voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TYGH110044
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Covid-19-vaccin
-
EyeGene Inc.Novotech (Australia) Pty LimitedActief, niet wervend
-
University of OxfordWervingCOVID-19 | Vaccin reactieVerenigd Koninkrijk
-
University of WashingtonCenters for Disease Control and PreventionWervingCOVID-19 | Vaccin AarzelingVerenigde Staten
-
Masaryk UniversityWervingBijwerking op vaccin | Covid-19-vaccinPolen, Canada, Verenigde Staten, Kroatië, Tsjechië, Estland, Ethiopië, Duitsland, Ghana, Mexico, Portugal, Russische Federatie, Servië, Slovenië
-
University of BariLebanese UniversityVoltooidVaccin Bijwerking | Geslacht | COVID-19 Vaccin BijwerkingItalië
-
Beijing 302 HospitalWervingCOVID-19 | Vaccin reactie | Patiënten met kankerChina
-
Chulalongkorn UniversityNational Vaccine Institute, Thailand; Chula Vaccine Research Center (ChulaVRC)... en andere medewerkersVoltooid
-
Korea University Guro HospitalAjou University School of Medicine; Korean Center for Disease Control and Prevention en andere medewerkersWervingOntsteking | Vaccin Bijwerking | Vaccin immuunrespons | COVID-19-vaccinatieKorea, republiek van
-
LifeBridge HealthWervingOntsteking | Vaccin Bijwerking | Trombose | Coronavirusbesmetting | Covid-19-vaccin | Vaccin responsVerenigde Staten
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Duke University; University of Washington en andere medewerkersBeëindigdVaccin Aarzeling | Covid-19-vaccinVerenigde Staten
Klinische onderzoeken op MVC-COV1901(3 Months)
-
Medigen Vaccine Biologics Corp.Voltooid
-
Medigen Vaccine Biologics Corp.VoltooidCovid19-vaccinTaiwan
-
Medigen Vaccine Biologics Corp.Voltooid
-
Medigen Vaccine Biologics Corp.Coalition for Epidemic Preparedness InnovationsVoltooid
-
Medigen Vaccine Biologics Corp.Voltooid
-
Chang Gung Memorial HospitalMedigen Vaccine Biologics Corp.Actief, niet wervendCOVID-19 | Doorbraak infectieTaiwan
-
Medigen Vaccine Biologics Corp.VoltooidCovid19-vaccinTaiwan
-
Medigen Vaccine Biologics Corp.Voltooid
-
Medigen Vaccine Biologics Corp.Voltooid
-
Medigen Vaccine Biologics Corp.VoltooidCovid19-vaccinTaiwan, Vietnam